EUCTR2017-005060-18-GB进行中（未招募）1 期
The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blind placebo-controlled, cross-over, single centre study. - RUPA v1.0
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •All of the below must apply:
- •1.Males and females 18-55 years
- •2.Capable of giving informed consent
- •3.Previous medical history of allergic reaction to peanut
- •4.Doctor’s diagnosis of peanut allergy (either reported in the previous medical history or diagnosis of peanut allergy at the screening visit -V1- by a physician other than the study doctor, as described in the trial Case Report Forms).
- •5.Reaction history should not be solely indicative of oral allergy syndrome (that is, only localised symptoms in and/or around the oral cavity)
- •6.Positive skin prick test result to peanut > 3mm and/or specific IgE to peanut =0.4kUa/L (ImmunoCAP Phadia)
- •7.Participant able to swallow capsules
- •8.Baseline systolic blood pressure of equal or over 100mmHg
- •9.Participant should be able to receive the following rescue medication, if needed (They should not have a contraindication to the use of this medication, as per study doctor’s judgement).
- •-Inhaled and IV salbutamol;
- •-inhaled and IM adrenaline;
- •-oral and IV antihistamines;
- •-Inhaled, oral or other systemic (e.g parenteral) corticosteroids.
- •10.Negative HLA-B*5801 status
- •11.Positive result on the peanut day of the DBPCFC (visits two and three), and the positive result to be on any dose up to and including the 100mg dose of peanut protein.
- •12.Negative challenge result on the placebo day of the DBPCFC (visits two and three).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Any of the below excludes someone from participating:
- •1.Females must be non-pregnant with no intention of becoming pregnant during the study.
- •Women of childbearing potential (<1 year post-menopausal) must agree to use (or are already on) one of the following acceptable birth control methods whilst they are enrolled in the trial:
- •-True complete abstinence when this is in line with the preferred and usual lifestyle of the participant;
- •-surgical sterilisation of either the female participant in the study or of her male partner, if he is the sole partner of the participant;
- •-established hormonal contraception (implantable, patch, oral or intramuscular [IM]) administered for at least one month prior to study medication administration;
- •-intrauterine device (IUD) or intrauterine system (IUS) with a failure rate of less than 1% per year inserted by a qualified physician, at least one month prior to study medication administration;
- •-double barrier method: condom and occlusive cap (diaphragm) with spermicidal foam/gel/film/cream/suppository
- •2.Serum pregnancy test will be conducted at screening, and urine pregnancy tests (sticks) will be conducted at all other visits apart from the two follow-up visits. In the event of a positive test, the participant will be withdrawn from the trial and the pregnancy will be reported to the Sponsor.
- •3.Females must be non-lactating.
- •Reports indicate that allopurinol and oxypurinol are excreted in human breast milk. Concentrations of 1.4 mg/litre allopurinol and 53.7 mg/litre oxypurinol have been demonstrated in breast milk from a woman taking allopurinol 300 mg/day. There is no data regarding the effects of allopurinol or its metabolites on the breastfed baby.
- •4.The participants should not be on medication that is contraindicated for the IMP or for the procedures of the trial:
- •-(due to interactions with allopurinol): Salicylates (e.g Aspirin), Uricosuric agents (e.g. febuxostat, probenecid), Phenytoin, Theophylline, Ampicillin, amoxicillin (e.g co-amoxiclav), Coumarin Anticoagulants (e.g. warfarin), Immunosuppressant and immunomodulatory drugs (e.g 6-mercaptopurine, azathioprine, cyclophosphamide, cyclosporin), doxorubicin, bleomycin, procarbazine, mechlorethamine, Antiretroviral drugs (e.g Didanosine), diuretics, Chlorpropamide, Captopril, Vidarabine (adenine arabinoside), ACE inhibitors.
- •-(due to interference with the study design): Beta-blocking agents, ACE inhibitors, Oral or other systemic corticosteroids, anti-IgE (omalizumab), SSRI antidepressant medication.
- •Also, the participant should not be on allopurinol.
- •5.Participants should not have participated in other clinical trials involving the use of an Investigational Medicinal Product (IMP) within the past 3 months.
- •6.There should be no previous history of a severe allergic reaction to peanut with confirmed lower respiratory symptoms or documented hypotension.
- •7.FEV1 should be no less than 70% predicted for age, gender and height
- •8.Participants should not be unable or unlikely to follow the trials procedures due to any issue (including communication issues such as language barrier).
- •9.The participant s
研究者
相似试验
已完成
不适用
Quercetin as Possible Supportive Therapy for Mild to Moderate HyperuricemiaHyperuricemiaNCT06591767Liaquat University of Medical & Health Sciences64
已完成
1 期
The Relationship Between Uric Acid and Inflammatory MarkersHealthy VolunteersNCT01323335National Institute on Aging (NIA)97
尚未招募
不适用
To study association between blood uric acid levels and nerve damage due to diabetesCTRI/2020/03/024273Afees Ahamed M A
Unknown
不适用
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD IndividualsNon-Alcoholic Fatty Liver DiseaseHyperuricemiaNCT05245890Ningbo No. 1 Hospital2,000
已完成
不适用
Assessment of relationship between serum uric acid levels and atherosclerosishyperuricemiaJPRN-UMIN000009135The University of Tokushima Medicine and Bioregulatory Sciences400